



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

EVITRADE Health Announces Signing of MOU#2 for CBD Creams and Oils with accompanying 50 ha Growing License for Wholly Owned Subsidiary C&C Cosmeceuticals Corp.

VANCOUVER, BC, Wednesday November 16, 2016 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF) (the “Company” or “EVITRADE”) announces that it has entered into a memorandum of understanding (“MOU#2”) dated November 15, 2016 with a formulator and licensed grower (the “Vendor”), based in Europe, to acquire for the company’s wholly owned subsidiary C&C Cosmeceuticals Corp. (C&C), all hemp, cannabis harvest and production from the 2016 growing season, all assets related to the cannabis or hemp strains, growing operation, production, sales rights, and associated goodwill (collectively, the “Assets2”) related to cannabis growing operation (subject to any and all regulatory and legal approvals, and final terms of a Definitive Agreement).

Pursuant to MOU#2, the acquisition of the Assets2 (the “Transaction2”) will be effected by the Company completing a business combination, merger/amalgamation or acquisition by issuing common shares (the “Consideration Shares”) to the Vendor to acquire all of the Assets2. The Consideration Shares will be issued at a deemed price of CAD \$2.25 per share, the date of the signed MOU#2.. The Consideration Shares will be subject to regulatory restrictions dependant on the manner in which Transaction2 is consummated and is subject to the signing and closing of a Definitive Agreement.

“Assuming the successful closing of this Transaction2, we are pleased to be able to acquire a European license to grow and produce on 50 ha of land, along with all related assets for the medical CBD creams and oils. The structure of the Vendor’s operation allows the business to be vertically integrated; ensuring our subsidiary has its quality controlled from a manufacturing perspective over all aspects of production. In addition the existing license can provide multiple revenue streams as it provides the capability to sell all aspects of the plant, including the oils (both with and without CBD) once the oil extraction from the 2016 season harvest has been completed. We continue to strive to deliver shareholder value and appreciate the positive and patient support of our many shareholders. Management looks forward to providing shareholders with material updates of this healthcare manufacturing business opportunity in the near future” said Syd Au, Chairman and CEO.

Contact:

Ron Ozols, Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email: info@auxellence.com

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLD)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

About C&C Cosmeceuticals Corp.

C&C Cosmeceuticals Corp. was founded in 2011 to develop, manufacture and market nutraceutical and cosmeceutical personal healthcare products and services. It was the predecessor company that acquired Auxellence Health Corporation, which is now named EVITRADE Health Systems Corp. and is currently a wholly owned subsidiary. As per the September 2, 2016 press release from the parent company, and the follow up November 9, 2016 press release from the parent company, C&C is likely to be voted upon to be dividended or divested from the company and all shareholders on record as of November 15th, 2016 will be entitled to vote on that motion, at the Annual General and Special Meeting and any shareholders that are officially holders of record as of December 15, 2016 in the parent company are expected to receive a pro-rata distribution of the shares in the subsidiary in the even the motion is successfully passed.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.